HLA-B*51 and Behcet Disease

Gül A., Ohno S.

OCULAR IMMUNOLOGY AND INFLAMMATION, cilt.20, sa.1, ss.37-43, 2012 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 20 Sayı: 1
  • Basım Tarihi: 2012
  • Doi Numarası: 10.3109/09273948.2011.634978
  • Dergi Adı: OCULAR IMMUNOLOGY AND INFLAMMATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.37-43
  • Anahtar Kelimeler: Behcet disease, HLA-B*51, HLA-B5, HLA-Bw4, KIR3DL1, MICA, MAJOR HISTOCOMPATIBILITY COMPLEX, HLA CLASS-I, GENOME-WIDE ASSOCIATION, MHC CLASS-I, CLINICAL-MANIFESTATIONS, FAMILIAL AGGREGATION, OCULAR INVOLVEMENT, CLOSE ASSOCIATION, CROSS-REACTIVITY, NONAMER PEPTIDES
  • İstanbul Üniversitesi Adresli: Evet

Özet

Behcet disease (BD) is a multisystem inflammatory disorder of unknown etiology. BD has a multifactorial pathogenesis, and genetics plays a critical role in the development of the disease. Association of HLA-B5/B*51 has been recognized as the strongest genetic susceptibility factor for BD discovered so far. Pathogenic role of HLA-B*51 in BD has yet to be clarified, and available data suggest that there is possibly no single mechanism associated with HLA-B*51. HLA-B*51 may accomplish its effects as a combination of different HLA class I-associated functions and/or structural properties of HLA-B*51 heavy chain. There is no evidence supporting the use of HLA-B*51 as a diagnostic or prognostic marker for BD, and more clinical data must be collected in addition to basic immunological studies to exploit the potential of HLA-B*51 as a biomarker for BD management.